In 1978 and 1980, the National Cancer Institute (NCI) tested Cancell/Cantron/Protocel in animal studies and determined that the mixture lacked substantial antitumor activity. Reviewed in 
In 1990 and 1991, samples of Cancell/Cantron/Protocel were evaluated in NCI's in vitro 60 Human Tumor Cell Line Screen. The test results are available online. The graphs and the numerical designations for each of the three cancer cell growth criteria (GI50, concentration required for 50% inhibition of cell growth; TGI, concentration required for total inhibition of cell growth; and LC50, concentration required for 50% cell lethality or death) are somewhat complicated, but a technical explanation is provided in the Appendix. There is little evidence that any of the constituents of Cancell/Cantron/Protocel would be available in the bloodstream of a patient in significant concentrations after its ingestion. Activity was seen in two-thirds of the cell lines, though at levels that would be roughly 275 times higher than the theoretical maximum concentration achievable in serum. Therefore, the in vitro effects are likely due to nonspecific effects of changes in salt concentration. Furthermore, cells in the NCI Tumor Cell Line Screen are grown in artificial media under conditions that do not truly mimic the in vivo situation in animals or humans, and that results obtained with the screen may not accurately reflect possible effects in humans. To place the findings for Cancell/Cantron/Protocel in perspective any conventional drug exhibiting this low level of in vitro activity in the NCI human cancer cell line screen would normally not be investigated further by NCI.
To assist readers in evaluating the results of human studies of complementary and alternative medicine (CAM) treatments for people with cancer, the strength of the evidence (i.e., the levels of evidence) associated with each type of treatment is provided whenever possible. To qualify for a level of evidence analysis, a study must:
Be published in a peer-reviewed scientific journal.
Report on therapeuticoutcome or outcomes, such as tumorresponse, improvement in survival, or measured improvement...
The principal manufacturers of Cancell/Cantron/Protocel have stated that they have performed numerous animal experiments with the mixture involving tens of thousands of mice. Reviewed in [1,2] Results of these experiments, however, have not been published in peer-reviewed scientific journals and no information beyond stating that some of the experiments tested the toxicity of Cancell/Cantron/Protocel has been provided.
Questionable methods of cancer management: Cancell/Entelev. CA Cancer J Clin 43 (1): 57-62, 1993 Jan-Feb.
Cancell Alternative Cancer Treatment. . Available online. Last accessed February 8, 2011.